PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL

A. Sharp, Anja Williams, Sarah Blagden, R. Plummer, D. Hochhauser, Matthew Krebs, Simon Pacey, J. Evans, Sarah Whelan, S. Nandakumar, S. Rogers, K. Jameson, F. Basile, J. Bono, H.-T Arkenau

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)1970-1971
Number of pages2
JournalHemaSphere
DOIs
Publication statusPublished - 23 Jun 2022

Cite this